Cargando…

Impact of sensitivity of human leucocyte antigen antibody detection by Luminex technology on graft loss at 1 year

BACKGROUND: The clinical relevance of the detection of human leucocyte antigen (HLA) antibodies in sera of renal transplant recipients by highly sensitive methods such as Luminex alone is uncertain and a matter of debate. The choice of output thresholds affects antibody detection and thus organ allo...

Descripción completa

Detalles Bibliográficos
Autores principales: Szatmary, Peter, Jones, James, Hammad, Abdul, Middleton, Derek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4400482/
https://www.ncbi.nlm.nih.gov/pubmed/26064487
http://dx.doi.org/10.1093/ckj/sft037
_version_ 1782367032926273536
author Szatmary, Peter
Jones, James
Hammad, Abdul
Middleton, Derek
author_facet Szatmary, Peter
Jones, James
Hammad, Abdul
Middleton, Derek
author_sort Szatmary, Peter
collection PubMed
description BACKGROUND: The clinical relevance of the detection of human leucocyte antigen (HLA) antibodies in sera of renal transplant recipients by highly sensitive methods such as Luminex alone is uncertain and a matter of debate. The choice of output thresholds affects antibody detection and thus organ allocation, yet there are no internationally agreed threshold levels. This study aims at evaluating our current practice of using an MFI threshold of 1000 in antibody detection. METHODS: We carried out a case–control study by looking at 761 renal transplant recipients at one unit between 2000 and 2010. Of these, there were 93 cases of graft loss within 1 year and stored serum samples of 40 cases were available for testing. Controls were selected (graft function >2 years) and individually matched according to age, sex, number of transplants and date of transplant. All 40 cases and 40 controls had negative crossmatch by complement-dependent cytotoxicity (CDC) at the time of transplant, and pre-transplant sera were re-analysed for the presence of detectable HLA and donor-specific antibodies (DSAs) using Luminex screen and single-antigen beads and MFI threshold values of 1000, 2000 and 4000. RESULTS: In nearly 48% of cases with graft loss within a year, HLA antibodies were detectable by Luminex when using a 1000 MFI threshold. This was 25% greater than in controls (P = 0.017). There was also a 15% increase in detected DSAs; however, statistical significance depends on the inclusion or exclusion of one specific case. Using MFI thresholds of 2000 and 4000, no DSAs were found in any long-term surviving grafts. CONCLUSIONS: Selection of appropriate MFI cut-off values influences the detection of DSAs and, thus, organ allocation. Using a threshold of 1000 led to the detection of DSAs in 5% of long-term graft survivors in our population and should be considered too sensitive. Using a detection threshold of 2000 is sufficiently sensitive and leads to clinically relevant detection of DSA.
format Online
Article
Text
id pubmed-4400482
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-44004822015-06-10 Impact of sensitivity of human leucocyte antigen antibody detection by Luminex technology on graft loss at 1 year Szatmary, Peter Jones, James Hammad, Abdul Middleton, Derek Clin Kidney J Original Contributions BACKGROUND: The clinical relevance of the detection of human leucocyte antigen (HLA) antibodies in sera of renal transplant recipients by highly sensitive methods such as Luminex alone is uncertain and a matter of debate. The choice of output thresholds affects antibody detection and thus organ allocation, yet there are no internationally agreed threshold levels. This study aims at evaluating our current practice of using an MFI threshold of 1000 in antibody detection. METHODS: We carried out a case–control study by looking at 761 renal transplant recipients at one unit between 2000 and 2010. Of these, there were 93 cases of graft loss within 1 year and stored serum samples of 40 cases were available for testing. Controls were selected (graft function >2 years) and individually matched according to age, sex, number of transplants and date of transplant. All 40 cases and 40 controls had negative crossmatch by complement-dependent cytotoxicity (CDC) at the time of transplant, and pre-transplant sera were re-analysed for the presence of detectable HLA and donor-specific antibodies (DSAs) using Luminex screen and single-antigen beads and MFI threshold values of 1000, 2000 and 4000. RESULTS: In nearly 48% of cases with graft loss within a year, HLA antibodies were detectable by Luminex when using a 1000 MFI threshold. This was 25% greater than in controls (P = 0.017). There was also a 15% increase in detected DSAs; however, statistical significance depends on the inclusion or exclusion of one specific case. Using MFI thresholds of 2000 and 4000, no DSAs were found in any long-term surviving grafts. CONCLUSIONS: Selection of appropriate MFI cut-off values influences the detection of DSAs and, thus, organ allocation. Using a threshold of 1000 led to the detection of DSAs in 5% of long-term graft survivors in our population and should be considered too sensitive. Using a detection threshold of 2000 is sufficiently sensitive and leads to clinically relevant detection of DSA. Oxford University Press 2013-06 /pmc/articles/PMC4400482/ /pubmed/26064487 http://dx.doi.org/10.1093/ckj/sft037 Text en © The Author 2013. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For permissions, please email: journals.permissions@oup.com http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Contributions
Szatmary, Peter
Jones, James
Hammad, Abdul
Middleton, Derek
Impact of sensitivity of human leucocyte antigen antibody detection by Luminex technology on graft loss at 1 year
title Impact of sensitivity of human leucocyte antigen antibody detection by Luminex technology on graft loss at 1 year
title_full Impact of sensitivity of human leucocyte antigen antibody detection by Luminex technology on graft loss at 1 year
title_fullStr Impact of sensitivity of human leucocyte antigen antibody detection by Luminex technology on graft loss at 1 year
title_full_unstemmed Impact of sensitivity of human leucocyte antigen antibody detection by Luminex technology on graft loss at 1 year
title_short Impact of sensitivity of human leucocyte antigen antibody detection by Luminex technology on graft loss at 1 year
title_sort impact of sensitivity of human leucocyte antigen antibody detection by luminex technology on graft loss at 1 year
topic Original Contributions
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4400482/
https://www.ncbi.nlm.nih.gov/pubmed/26064487
http://dx.doi.org/10.1093/ckj/sft037
work_keys_str_mv AT szatmarypeter impactofsensitivityofhumanleucocyteantigenantibodydetectionbyluminextechnologyongraftlossat1year
AT jonesjames impactofsensitivityofhumanleucocyteantigenantibodydetectionbyluminextechnologyongraftlossat1year
AT hammadabdul impactofsensitivityofhumanleucocyteantigenantibodydetectionbyluminextechnologyongraftlossat1year
AT middletonderek impactofsensitivityofhumanleucocyteantigenantibodydetectionbyluminextechnologyongraftlossat1year